(Q53130957)

English

The impact of frontline risk-adapted strategy on the overall survival of patients with newly diagnosed multiple myeloma: an analysis of the Singapore multiple myeloma study group.

scientific article published on 21 June 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22553948

The impact of frontline risk-adapted strategy on the overall survival of patients with newly diagnosed multiple myeloma: an analysis of the Singapore multiple myeloma study group. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22553948

0 references

multiple myeloma

1 reference

based on heuristic

inferred from title

author name string

Daryl Tan

1

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22553948

Kiat H Ong

2

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22553948

Liang P Koh

3

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22553948

Siew S Wong

4

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22553948

Myat T Khin

5

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22553948

Lai H Lee

6

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22553948

Yeow T Goh

7

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22553948

Wee J Chng

8

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22553948

publication date

21 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22553948

European Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22553948

89

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22553948

2

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22553948

136-144

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22553948

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

Suppression of abnormal karyotype predicts superior survival in multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

Prognostic factors in multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

352. Note: Conservatism of the Approximation Σ(O - E) 2 /E in the Logrank Test for Survival Data or Tumor Incidence Data

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

Analysis of survival by tumor response.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

Many and multiple myeloma(s)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

Genetics and cytogenetics of multiple myeloma: a workshop report

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

Recent major improvement in long-term survival of younger patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

CR represents an early index of potential long survival in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

Cytogenetic Abnormalities Correlate with the Plasma Cell Labeling Index and Extent of Bone Marrow Involvement in Myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2012.01797.X

21 January 2018

Identifiers

10.1111/J.1600-0609.2012.01797.X

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22553948

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22553948

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53130957&oldid=2148618423"